Patents Assigned to Protalix Ltd.
-
Publication number: 20240002814Abstract: A modified uricase is described herein, as well as a method of reducing a level of uric acid by contacting a medium with the modified uricase. The modified uricase comprises a uricase polypeptide crosslinked by at least one bifunctional linking moiety that comprises a poly(alkylene glycol) moiety. A molecular weight of the bifunctional linking moiety is from about 1.5 kDa to about 4 kDa, and/or the modified uricase comprises a plurality of polypeptides having the amino acid sequence SEQ ID NO: 2. Further described is a polypeptide having the amino acid sequence SEQ ID NO: 2. A process of preparing the modified uricase is also described, comprising contacting the polypeptide with a crosslinking agent that comprises a poly(alkylene glycol) moiety and at least two aldehyde groups, to obtain a conjugate; and contacting the conjugate with a reducing agent.Type: ApplicationFiled: November 3, 2021Publication date: January 4, 2024Applicant: Protalix Ltd.Inventors: Ilya RUDERFER, Yakir NATAF, Gil ARVATZ, Uri HANANIA, Tamar ARIEL, Shelly ROZEN, Yael HAYON
-
Publication number: 20230416707Abstract: A modified DNase protein is described herein as well as pharmaceutical compositions comprising same, the modified DNase protein comprising a DNase polypeptide attached to at least two poly(alkylene glycol) moieties. Further described herein is a process of preparing a modified DNase protein, the process comprising: contacting the polypeptide with an agent that comprises a poly(alkylene glycol) attached to an aldehyde group, to obtain a conjugate of the polypeptide and the agent; and contacting the conjugate with a reducing agent.Type: ApplicationFiled: October 7, 2021Publication date: December 28, 2023Applicant: Protalix Ltd.Inventors: Ilya RUDERFER, Liat FUX, Yael HAYON
-
Publication number: 20230374447Abstract: DICER-liker knock-out plant cells are provided. Accordingly, there is provided an isolated plant cell in suspension comprising loss of function mutations in all alleles of at least two genes selected from the group consisting of DCL2, DCL4, RDR1, RDR2 and RDR6 in said plant cell. Also provided are methods of abolishing expression and/or activity of at least two genes selected from the group consisting of DCL2, DCL4, RDR1, RDR2 and RDR6 in a plant cell.Type: ApplicationFiled: October 5, 2021Publication date: November 23, 2023Applicant: Protalix Ltd.Inventors: Uri HANANIA, Maor SHEVA
-
Patent number: 11814657Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.Type: GrantFiled: December 20, 2021Date of Patent: November 14, 2023Assignee: Protalix Ltd.Inventors: Lilach Chen Zeltsburg, Ilya Ruderfer, Avidor Shulman, Liat Fux, Yulia Ugortsev, Hagit Neta, Sivan Gelley, Elad Lavee Laviad, Yoseph Shaaltiel
-
Publication number: 20230022576Abstract: A nucleic acid construct is disclosed which is removable after transformation. Methods of using same are disclosed as well.Type: ApplicationFiled: November 19, 2019Publication date: January 26, 2023Applicant: Protalix Ltd.Inventors: Maor SHEVA, Uri HANANIA
-
Publication number: 20220106578Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.Type: ApplicationFiled: December 20, 2021Publication date: April 7, 2022Applicant: Protalix Ltd.Inventors: Lilach CHEN ZELTSBURG, Ilya RUDERFER, Avidor SHULMAN, Liat FUX, Yulia UGORTSEV, Hagit NETA, Sivan GELLEY, Elad LAVEE LAVIAD, Yoseph SHAALTIEL
-
Patent number: 11225648Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.Type: GrantFiled: January 4, 2016Date of Patent: January 18, 2022Assignee: Protalix Ltd.Inventors: Lilach Chen Zeltsburg, Ilya Ruderfer, Avidor Shulman, Liat Fux, Yulia Ugortsev, Hagit Neta, Sivan Gelley, Elad Lavee Laviad, Yoseph Shaaltiel
-
Patent number: 10870842Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: March 18, 2019Date of Patent: December 22, 2020Assignee: PROTALIX LTD.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 10730925Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.Type: GrantFiled: July 26, 2018Date of Patent: August 4, 2020Assignee: Protalix Ltd.Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Tami Ariel, Svetlana Gingis-Velitski
-
Publication number: 20200155654Abstract: Methods of treating Fabry disease via administration of stabilized plant recombinant human alpha galactosidase protein comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety, and unit dosages of protein are disclosed herein. The disclosed protocols are safe, have greater than 2 week intervals between administrations and exhibit important improvement in patient's disease parameters, in terms of reduced Gb3 accumulation, pain and GI parameters, kidney and cardiac stabilization in the clinical setting.Type: ApplicationFiled: January 5, 2018Publication date: May 21, 2020Applicant: Protalix Ltd.Inventors: Einat ALMON, Raul CHERTKOFF, Sari ALON, Yoseph SHAALTIEL
-
Patent number: 10364413Abstract: A reusable, disposable device for culturing plant tissues or cells including a non-rigid container having dimensions and gas exchange ports designed for maintaining oxygen saturation and shear forces suitable for culturing plant tissue or cells in 400 liters or more of culture medium is provided. Also provided are methods for producing a catalytically active human recombinant protein in a plant cell, using the disposable device of one of the embodiments of the instant specification.Type: GrantFiled: May 5, 2008Date of Patent: July 30, 2019Assignee: Protalix Ltd.Inventors: Yoseph Shaaltiel, Yair Kirshner, Alon Shtainiz, Yaron Naos, Yftach Shneor
-
Patent number: 10280414Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: June 29, 2017Date of Patent: May 7, 2019Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Publication number: 20180327476Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.Type: ApplicationFiled: July 26, 2018Publication date: November 15, 2018Applicant: Protalix Ltd.Inventors: Yoseph SHAALTIEL, Uri HANANIA, Tali KIZHNER, Tami ARIEL, Svetlana GINGIS-VELITSKI
-
Publication number: 20180291084Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.Type: ApplicationFiled: June 13, 2018Publication date: October 11, 2018Applicant: Protalix Ltd.Inventors: Yoseph SHAALTIEL, Uri HANANIA, Tali KIZHNER, Tami ARIEL, Svetlana GINGIS-VELITSKI, Myriam GOLEMBO
-
Patent number: 10087232Abstract: A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.Type: GrantFiled: March 6, 2014Date of Patent: October 2, 2018Assignees: Protalix Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Yaron Ilan, Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Tami Ariel, Svetlana Gingis-Velitski
-
Patent number: 10000551Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.Type: GrantFiled: September 10, 2015Date of Patent: June 19, 2018Assignee: Protalix Ltd.Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Tami Ariel, Svetlana Gingis-Velitski, Myriam Golembo
-
Publication number: 20180148703Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: June 29, 2017Publication date: May 31, 2018Applicant: Protalix Ltd.Inventors: Avidor SHULMAN, Ilya RUDERFER, Tehila BEN-MOSHE, Talia SHEKHTER, Yaniv AZULAY, Tali KIZHNER, Yoseph SHAALTIEL
-
Patent number: 9732333Abstract: Nucleic acid expression constructs are provided and, more particularly, nucleic acid constructs for expression of human alpha-galactosidase in plant cells, cells expressing the nucleic acid construct, producing the human alpha-galactosidase and uses thereof.Type: GrantFiled: September 7, 2011Date of Patent: August 15, 2017Assignee: Protalix Ltd.Inventors: Avidor Shulman, Uri Hanania, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 9708595Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: November 10, 2015Date of Patent: July 18, 2017Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben Moshe, Talia Shekhter, Yaniv Azulay, Yoseph Shaaltiel, Tali Kizhner
-
Patent number: 9603906Abstract: An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.Type: GrantFiled: January 31, 2013Date of Patent: March 28, 2017Assignee: Protalix Ltd.Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Yulia Matiuhin, Liat Fux, Avidor Shulman